Compare Humana Inc (HUM) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Oatly Group AB - ADR — how do they compare? Humana Inc trades at $373.38 (market cap $46.31B), while Oatly Group AB - ADR trades at $12.93 (market cap $421.56M). The key difference: Humana Inc is far larger — about 109.9× Oatly Group AB - ADR's market cap, and Humana Inc pays a 0.92% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| HUM | OTLY | |
|---|---|---|
Market Cap | $46.31B | $421.56M |
Sector | Health | Consumer Staples |
52-Week High | $409.42 | $18.54 |
52-Week Low | $163.67 | $8.03 |
Enterprise Value | $53.67B | $925.97M |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Oatly (OTLY) trades at $13.72, up 0.22% with a bullish technical signal driven by moving averages and oversold RSI levels. Revenue growth improved to $862.46M in 2025, though net losses persist at -$152.77M. Recent Q2 2026 results beat EPS expectations, prompting a raised full-year revenue outlook to $925M, fueling a 29% stock surge on July 22, 2026 (GlobeNewsWire). The company shows progress toward adjusted EBITDA positivity, but cash burn remains a concern.
The outlook hinges on execution of margin expansion and cash flow improvement. Risks include high debt-to-asset ratio (66.53% in 2025) and intense competition. Analyst consensus is mixed with 44% buy ratings, but institutional sentiment is cautious due to profitability challenges. Upside potential exists if Oatly achieves sustained EBITDA positivity and reduces cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
